Are you Dr. Chui?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 61 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3181 Sw Sam Jackson Park Rd
Mail Code L586, Mnp 3208
Portland, OR 97239Phone+1 503-494-6594- Is this information wrong?
Summary
- Dr. Stephen Chui, MD is an oncologist in Portland, Oregon. He is currently licensed to practice medicine in Oregon. He is affiliated with OHSU Hospital and Portland HCS.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004- Duke University HospitalResidency, Internal Medicine, 1996 - 1999
Duke University School of MedicineClass of 1996
Certifications & Licensure
OR State Medical License 2006 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy Start of enrollment: 2011 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 152 citationsAtezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A. Emens, Luciana Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiss, Véronique Diéras, Hiroji Iwata, Carlos H. Barrios, Marina Nechaeva, Anh Nguyen-Duc, ...> ;Journal of the National Cancer Institute. 2021 Aug 2
- Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice.Joyce O'Shaughnessy, Leisha A. Emens, Stephen Y. Chui, Wei Wang, Kenneth Russell, Shih-Wen Lin, Carlos Flores Avile, Patricia Luhn, Andreas Schneeweiss> ;Current Oncology. 2021 Jul 17
- 75 citationsPD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.Hope S. Rugo, Sherene Loi, Sylvia Adams, Peter Schmid, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Diéras, Eric P. Winer, Mark M. Kockx, Dieter Pee...> ;Journal of the National Cancer Institute. 2021 Jun 7
- Join now to see all
Press Mentions
Panel Tells FDA to Keep Atezolizumab Approval in TNBCApril 28th, 2021- FDA Panel Questions Roche's Tecentriq-Abraxane Combo in Breast Cancer, but Votes to Keep Approval in Place for NowApril 27th, 2021
Hospital Affiliations
Portland HCSPortland, Oregon
OHSU HospitalPortland, Oregon
